UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
January 12, 2005
Commission File Number 0-21392
AMARIN CORPORATION PLC
(Translation of registrant's name into English)
7 Curzon Street
London W1J 5HG
England
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
Attachment:
Material Events
(a) Amarin Corporation announces positive data from Phase IIa studies using
Miraxion to treat unresponsive depression.
This report on Form 6-K is hereby incorporated by reference
in (a) the registration statement on Form F-3 (Registration No.
333-104748) of Amarin Corporation plc and in the prospectus
contained therein, (b) the registration statement on Form F-3
(Registration No. 333-13200) of Amarin Corporation plc and in the
prospectus contained therein, (c) the registration statement on
Form F-3 (Registration No. 333-12642) of Amarin Corporation plc and
in the prospectus contained therein, (d) the registration statement
on Form F-3 (Registration No. 333-121431) of Amarin Corporation plc and
in the prospectus contained therein and (e) the registration statement
on Form F-3 (Registration No. 333-121760) of Amarin Corporation plc and
in the prospectus contained therein,, and this report on Form 6-K
shall be deemed a part of each such registration statement from the
date on which this report is filed, to the extent not superseded by
documents or reports subsequently filed or furnished by Amarin
Corporation plc under the Securities Act of 1933 or the Securities
Exchange Act of 1934.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
AMARIN CORPORATION PLC
By: /s/ JONATHAN LAMB
Name: Jonathan Lamb
Title: Secretary
Date: January 12, 2005
EXHIBIT INDEX
Index to Exhibits
Exhibit Item Sequentially Numbered Page
(a) Material event description 4
Contact:
Rick Stewart
Chief Executive Officer
Amarin Corporation plc
Phone: +44 (0) 207 907 2442
investor.relations@amarincorp.com
Alan Cooke
Chief Financial Officer
Amarin Corporation plc
Phone: +44 (0) 207 907 2442
AMARIN CORPORATION ANNOUNCES POSITIVE DATA FROM TWO PHASE IIA
STUDIES USING MIRAXION(TM) TO TREAT UNRESPONSIVE DEPRESSION
- Amarin identifies characteristics of depressed
patients responsive to Miraxion(TM) -
LONDON, United Kingdom, January 12, 2005 - Amarin Corporation plc (NASDAQSC:
AMRN) today announced positive data analysis from two exploratory phase IIa
clinical studies using Miraxion (formerly referred to as LAX-101c) to treat
depression. An analysis of the data from the two studies identifies a
significant clinical benefit with Miraxion for a sub-group of patients with
specific symptomology.
In a recent exploratory phase IIa study, Miraxion was used as monotherapy in 77
patients with a new episode of depression in a six-week trial. In this study it
was prespecified, that the presence of specific depression symptomology
(patients with melancholic vegetative symptoms) at the time of entry to the
study (baseline), would predict response. In an exploratory analysis the
Bech-Depression Scale, a subscale of the Hamilton Depression Rating Scale,
which defines the affective core symptoms of depression, was used as the
outcome variable. Miraxion achieved statistical significance over placebo in
the sub-group of patients meeting these criteria.
In addition, using identical symptom-specific methodology, statistically
significant results were obtained by reanalyzing the dataset from a published
(Peet and Horrobin, 2002, Archives of General Psychiatry, volume 59, pages
913-919) randomized placebo controlled study in treatment unresponsive
depression, where Miraxion was used as an adjunct therapy with standard
depression treatments.
It is estimated that depressed patients with these symptoms may represent
approximately 20-30% of all patients with depression.
Amarin filed a patent covering this intellectual property in late 2004 and
intends to publish the full results from the monotherapy study later this year.
Rick Stewart, Chief Executive Officer of Amarin commented, "The data analyzed
from these studies show significant clinical benefit for a specific sub-group of
patients with depression, when used as either monotherapy or as adjunct therapy.
This data will be an important component in the design of subsequent clinical
trials. It will allow us to more accurately target patients with depression
that may respond to Miraxion."
About Amarin Corporation
Amarin Corporation is a neuroscience company focused on the development and
commercialisation of novel drugs for the treatment of neurological disorders
affecting the central nervous system.
For press releases and other corporate information, visit our website at
http://www.amarincorp.com.
Statements in this press release that are not historical facts are forward-
looking statements that involve risks and uncertainties which may cause the
Company's actual results in future periods to be materially different from any
performance suggested herein. Such risks and uncertainties include, without
limitation, the uncertainty of entering into and consummating a definitive
agreement on terms acceptable to the parties, the inherent uncertainty of
pharmaceutical research, product development and commercialization, the impact
of competitive products and patents, as well as other risks and uncertainties
detailed from time to time in periodic reports. For more information, please
refer to Amarin Corporation's Annual Report for 2003 on Form 20-F and its Form
6-Ks as filed with the U.S. Securities and Exchange Commission. The company
assumes no obligation to update information on its expectations.